Amendment: SEC Form SC 13G/A filed by Zevra Therapeutics Inc.
$ZVRA
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/8/2025 | $25.00 | Overweight | Cantor Fitzgerald |
| 10/7/2024 | $20.00 | Buy | Guggenheim |
| 9/24/2024 | $17.00 | Mkt Outperform | JMP Securities |
| 9/24/2024 | $18.00 → $25.00 | Buy | Maxim Group |
| 4/2/2024 | $12.00 → $18.00 | Buy | Maxim Group |
| 3/12/2024 | Outperform | William Blair | |
| 3/17/2023 | $12.00 | Buy | Maxim Group |
SC 13G - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)
SC 13G/A - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)
SC 13G/A - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)
10-Q - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)
8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)
CELEBRATION, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced its upcoming addition to the Nasdaq Biotechnology Index (NASDAQ:NBI) ("NBI") as part of the annual reconstitution of the 2024 Nasdaq indexes. Zevra's inclusion in the NBI will be effective after the U.S. market opens on Monday, December 23, 2024. "The past year has been transformational for Zevra as we continue to drive awareness among the investment community and we are proud to be added to the Nasdaq Biotechnology Index, which further raises our profile giv
CELEBRATION, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced organizational changes designed to accelerate its transformation into a leading rare disease therapeutics company. The company announced that it is consolidating its development and scientific functions under Adrian Quartel, M.D., FFPM, Chief Medical Officer. Adrian will be responsible for clinical development, quality assurance, and regulatory and scientific affairs. As part of these changes, Christal M.M. Mickle, Chief Development Officer, and Sven Guenther, Ph
CELEBRATION, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced that Neil F. McFarlane, President and Chief Executive Office of Zevra, will participate in the following December investor events. Piper Sandler 36th Annual Healthcare Conference, on Wednesday, December 4, 2024, at 10:30 a.m. ET.Oppenheimer Movers in Rare Disease Summit Elevator Pitches from Rare Disease Companies with Key Near-term, Potentially Stock-moving Catalysts, on Thursday, December 12, 2024, at 2:45 p.m. ET as part of an invitation-only event hosted by O
Rahsaan W. Thompson appointed as Chief Legal Officer, Secretary and Compliance Officer Alison Peters appointed as Chief People Officer CELEBRATION, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the appointments of Rahsaan W. Thompson as Chief Legal Officer, Secretary and Compliance Officer, and Alison Peters as Chief People Officer. Both Mr. Thompson and Ms. Peters bring deep expertise in building high-performing teams which will be essential to deliver success through the Company's next phase of growth. "We are thrilled to welcome both Rahsaan and Alison to the Zevra team as w
CELEBRATION, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, Zevra's President and Chief Executive Officer, has issued a Letter to Stockholders providing a review of key accomplishments and outlook for 2024. Dear Stockholders, It is hard for me to believe that April 2024 marks six months since the start of my tenure as Zevra's President and Chief Executive Officer in October 2023. From that time, and even prior to my official start date, I began a listening tour, seeking feedback from many of Zevra's stakeholders – stockholders, investors, employees, patie
CELEBRATION, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the appointment of Alvin Shih, MD, MBA, to the Company's Board of Directors (Board) effective as of January 20, 2024. Dr. Shih has extensive experience in biotechnology leadership and rare disease therapeutics development and currently serves as President and CEO of Catamaran Bio, a biotechnology company developing cell therapies for multiple oncologic indications. "We are honored to welcome Dr. Shih to our Board as we advance our therapeutic portfolio of product candidates in multiple rare disease indications," said Tamar
Cantor Fitzgerald resumed coverage of Zevra Therapeutics with a rating of Overweight and set a new price target of $25.00
Guggenheim initiated coverage of Zevra Therapeutics with a rating of Buy and set a new price target of $20.00
JMP Securities initiated coverage of Zevra Therapeutics with a rating of Mkt Outperform and set a new price target of $17.00
CELEBRATION, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced it will report third quarter financial results and provide a corporate update on Tuesday, Nov. 12, 2024. The Company will issue a news release after the market closes and host a conference call/audio webcast at 4:30 p.m. ET that day. The corporate update will include recent progress with the commercial launches of MIPLYFFA™ and OLPRUVA® as well as the Company's clinical stage programs. A link to the audio webcast will be accessible on the "Events & Presentations"
MIPLYFFA is the first FDA-approved treatment for Niemann-Pick disease type C (NPC), an ultra-rare and progressive neurodegenerative disease MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of NPC in adults and pediatric patients 2 years of age and older Zevra receives rare pediatric disease priority review voucher in conjunction with approval Company launches AmplifyAssist™ patient support program Conference call and webcast set for 8:00 a.m. EDT on Monday, Sept. 23, 2024 CELEBRATION, Fla., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage rare disease therap
CELEBRATION, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced that it will host a conference call and audio webcast on Tuesday, August 13, 2024, at 4:30 p.m. ET, to review its corporate and financial results for the second quarter of 2024. The link to the audio webcast will be accessible via the Investor Relations section of the Company's website, https://investors.zevra.com/. To join the meeting by conference call, use the dial-in information below. (800) 225-9448 (U.S.)+1 (203) 518- 9708 (International)Conference ID: ZVRAQ224 An archive of the webcast will be available for 90 da
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)